TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11770694

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9189306

Group type: EXPERIMENTAL
Intervention: Glucose (GLU) feeding
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fructose (FRU) feeding
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sweetened placebo (PLA)
Number of subjects: 7
Study: 7920886

Group type: EXPERIMENTAL
Intervention: High resolution ultrasonography (US)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Tc‐99m scintigraphy
Number of subjects: 177
Study: 3538446

Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 150

Group type: COMPARATOR
Intervention: Oral trimeprazine, droperidol and methadone (TDM)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No sedative medication (unsedated group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 150

Group type: COMPARATOR
Intervention: TDM
Number of subjects: 150
Study: 31270962

Group type: EXPERIMENTAL
Intervention: Total sleep duration
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Nap duration
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Sleep variability
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Sleep timing
Number of subjects: 202
Study: 29975268

Group type: EXPERIMENTAL
Intervention: 1 week immobilization
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 3 weeks immobilization
Number of subjects: 133

Group type: COMPARATOR
Intervention: 6 weeks immobilization
Number of subjects: 133
Study: 26852375

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention program (PIP) with 12 weekly group sessions
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 223
Study: 24892447

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard trial consent materials (control group)
Number of subjects: 146
Study: 22409104

Group type: EXPERIMENTAL
Intervention: Working in a functional dyad (team)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Working alone
Number of subjects: 0
Study: 19817814

Group type: EXPERIMENTAL
Intervention: Continuous electrical stimulation of the hippocampus bilaterally (on)
Number of subjects: 2

Group type: COMPARATOR
Intervention: No stimulation (off)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Continuous electrical stimulation of the hippocampus bilaterally
Number of subjects: 2
Study: 18047891

Group type: EXPERIMENTAL
Intervention: 1-minute stage exercise testing protocol
Number of subjects: 42

Group type: COMPARATOR
Intervention: 3-minute stage exercise testing protocol
Number of subjects: 42
Study: 15228199

Group type: EXPERIMENTAL
Intervention: Cementum annulation technique applied to older individuals (n=34)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cementum annulation technique applied to younger individuals (n=24)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Comparison of age determination between men and women
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Comparison of modern teeth and teeth from the 19th century
Number of subjects: 58
Study: 12399222

Group type: EXPERIMENTAL
Intervention: Cirrhosis group (n=6)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hepatitis group (n=3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy volunteers (n=6)
Number of subjects: 15
Study: 9657461

Group type: EXPERIMENTAL
Intervention: 10% MCT/LCT fat emulsion
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 20% MCT/LCT fat emulsion
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LCT fat emulsion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Glucose alone (Control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All fat emulsions
Number of subjects: 25
Study: 7624387

Group type: EXPERIMENTAL
Intervention: Paroxetine combined with zotepine or haloperidol
Number of subjects: 14
Study: 2697729

Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation
Number of subjects: 400

Group type: COMPARATOR
Intervention: Low-calcium diet
Number of subjects: 400
Study: 127542

Group type: EXPERIMENTAL
Intervention: DHEA‐S
Number of subjects: 15

Group type: COMPARATOR
Intervention: NaCl (Control)
Number of subjects: 15
Study: 31170361

Group type: EXPERIMENTAL
Intervention: Intermittent Intensive Insulin Therapy (IIT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metformin (Control)
Number of subjects: 24
Study: 28616851

Group type: EXPERIMENTAL
Intervention: Aerobic interval training for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 40
Study: 26116037

Group type: EXPERIMENTAL
Intervention: Telemetric monitoring
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional medical consultation
Number of subjects: 40
Study: 23631965

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (2 turns of activation (0.4 mm) per day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Slow maxillary expansion (2 turns of activation (0.4 mm) per week until 8 mm of expansion)
Number of subjects: 33
Study: 21596190

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine S(+) 0.050 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine S(+) 0.125 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine S(+) 0.250 mg/kg
Number of subjects: 30
Study: 19389820

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) with insulin glargine and lispro
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 50

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 50
Study: 17321667

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA)
Number of subjects: 77
Study: 15098043

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EBM principles and application
Number of subjects: 0
Study: 11255387

Group type: EXPERIMENTAL
Intervention: Ibutilide (0.003 mg/kg), infused intravenously for 10 minutes.
Number of subjects: 58
Study: 9572724

Group type: EXPERIMENTAL
Intervention: audio computer‐assisted self‐interviewing (audio‐CASI)
Number of subjects: 1690

Group type: COMPARATOR
Intervention: traditional self‐administered questionnaire
Number of subjects: 1690
Study: 8186337

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg each morning, placebo at bedtime)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Ranitidine (150 mg each morning and at bedtime)
Number of subjects: 158
Study: 2896139

Group type: EXPERIMENTAL
Intervention: Delayed-release mesalazine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Enteric-coated sulfasalazine
Number of subjects: 100
Study: 31560780

Group type: COMPARATOR
Intervention: MBCT
Number of subjects: 245

Group type: COMPARATOR
Intervention: eMBCT
Number of subjects: 245
Study: 28985228

Group type: EXPERIMENTAL
Intervention: Lifestyle coaching plus care coordination (N = 138)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Care coordination alone (N = 142)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Treatment as usual (N = 148)
Number of subjects: 428
Study: 25752936

Group type: EXPERIMENTAL
Intervention: BOLD hypercapnic/hyperoxic responses
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CBF hypercapnic response
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Resting CBF
Number of subjects: 8
Study: 23427212

Group type: EXPERIMENTAL
Intervention: Closed-loop anaesthesia system
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (manual administration)
Number of subjects: 186
Study: 22352122

Group type: EXPERIMENTAL
Intervention: Early titration (E) with irbesartan/hydrochlorothiazide 150/12.5 mg for 2 weeks, then up-titrated to 300/25 mg at weeks 2 and 6
Number of subjects: 795

Group type: COMPARATOR
Intervention: Late titration (L) with irbesartan/hydrochlorothiazide 150/12.5 mg for 6 weeks, then up-titrated to 300/25 mg at week 6
Number of subjects: 795
Study: 19153936

Group type: EXPERIMENTAL
Intervention: Total cholesterol (TC)
Number of subjects: 2299

Group type: EXPERIMENTAL
Intervention: Triglycerides (TG)
Number of subjects: 2299

Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-c)
Number of subjects: 2299

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 2299

Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment score (HOMA)
Number of subjects: 2299

Group type: EXPERIMENTAL
Intervention: Clustering of CVD risk factors
Number of subjects: 2299
Study: 16679897

Group type: EXPERIMENTAL
Intervention: AQUACEL Ag Hydrofiber dressing with silver
Number of subjects: 84

Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 84
Study: 14765987

Group type: EXPERIMENTAL
Intervention: l-thyroxine treatment regimen
Number of subjects: 11
Study: 11083889

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (800‐1200 mg/day)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Imipenem (2‐4 g/day)
Number of subjects: 149
Study: 9068468

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (250 mg b.i.d.)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral ciprofloxacin and Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin treatment
Number of subjects: 70
Study: 8251019

Group type: EXPERIMENTAL
Intervention: Prewarmed group (warming blanket for > or = 90 min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unwarmed group (not covered)
Number of subjects: 16
Study: 2947734

Group type: EXPERIMENTAL
Intervention: Thiethylperazine (6.5 mg p.o. every 8 h for 5 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Thiethylperazine (6.5 mg p.o. every 8 h for 5 days) plus amitriptyline (25 mg p.o. every 8 h for 5 days)
Number of subjects: 26
Study: 31671189

Group type: EXPERIMENTAL
Intervention: Perspective-taking group (observers instructed to take the perspective of the pain participant)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no perspective-taking instruction)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups (perspective-taking and control)
Number of subjects: 122
Study: 29705442

Group type: EXPERIMENTAL
Intervention: Cranberry capsule
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Training about UTIs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 26777765

Group type: EXPERIMENTAL
Intervention: Multidirectional power toothbrush (PT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: American Dental Association reference manual toothbrush (MT)
Number of subjects: 107
Study: 24509962

Group type: EXPERIMENTAL
Intervention: Sample group (received a demonstration on how to apply the medication using a product sample)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No sample group (no demonstration)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sample group
Number of subjects: 17

Group type: COMPARATOR
Intervention: No sample group
Number of subjects: 17
Study: 22910161

Group type: EXPERIMENTAL
Intervention: Structured training on box trainers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 40
Study: 21211344

Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoidal artery ligation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Operative procedures for prolapse and hemorrhoids
Number of subjects: 92
Study: 18677882

Group type: EXPERIMENTAL
Intervention: Tailored feedback letters
Number of subjects: 2827

Group type: COMPARATOR
Intervention: Generic feedback letters
Number of subjects: 2827

Group type: EXPERIMENTAL
Intervention: Tailored information with action-planning feedback
Number of subjects: 2827
Study: 15963129

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA+)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (CMA-)
Number of subjects: 71
Study: 12575974

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg verapamil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 30
Study: 11909562

Group type: EXPERIMENTAL
Intervention: Gold-coated stents (group B, n = 103)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Uncoated stents (group A, n = 101)
Number of subjects: 204
Study: 9819291

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) at high dose (800 micrograms twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) at high dose (800 micrograms twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7641720

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous propofol supplemented with nitrous oxide (Group III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone induction, isoflurane and nitrous oxide (Group I)
Number of subjects: 60
Study: 2475699

Group type: EXPERIMENTAL
Intervention: Falipamil 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Falipamil 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Falipamil
Number of subjects: 12
Study: 1093666

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 9

Group type: COMPARATOR
Intervention: 5-fluorouracil and cyclophosphamide
Number of subjects: 9

Group type: COMPARATOR
Intervention: Crossover treatment (Adriamycin to 5-fluorouracil and cyclophosphamide)
Number of subjects: 9
Study: 31174929

Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body‐oriented Therapy (MABT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MABT
Number of subjects: 10
Study: 31556659

Group type: EXPERIMENTAL
Intervention: SMART (smartphone application)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: GROUP (group-based BWL condition)
Number of subjects: 276

Group type: COMPARATOR
Intervention: CONTROL (control condition)
Number of subjects: 276
Study: 28102014

Group type: EXPERIMENTAL
Intervention: Group A (banded two‐arm Hyrax)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Group B (banded four‐arm Hyrax)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (RME)
Number of subjects: 35
Study: 26579797

Group type: EXPERIMENTAL
Intervention: Low-sodium wheat bread rich in potassium, GABA, and ACEI peptides (LSB+G)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional wheat bread (CB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-sodium wheat bread enriched in potassium (LSB)
Number of subjects: 30
Study: 24280478

Group type: EXPERIMENTAL
Intervention: Group music therapy (60-min sessions, twice a week for a total of ten sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (no music therapy)
Number of subjects: 80
Study: 21787474

Group type: EXPERIMENTAL
Intervention: Xuebijing treatment group (n=39, received bundle treatment + Xuebijing treatment)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine group (n=25, received routine bundle treatment)
Number of subjects: 64
Study: 19420392

Group type: EXPERIMENTAL
Intervention: School-based intervention promoting physical activity and healthy eating; details on dosage and duration not specified
Number of subjects: 2155

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 2155
Study: 17014519

Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for calcium-phosphate product
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for glycosylated hemoglobin
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for blood pressure
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for hemoglobin
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for parathyroid hormone
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for low-density lipoprotein
Number of subjects: 197
Study: 15308996

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 500

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 500
Study: 10694140

Group type: EXPERIMENTAL
Intervention: Low Volume Taper (LVT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moderate Volume Taper (MVT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Taper LICT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Taper HIIT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 8
Study: 9463178

Group type: EXPERIMENTAL
Intervention: Guilmen‐Pontonnier suture (Group A)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Blair‐Donatti suture (Group B)
Number of subjects: 202
Study: 8167624

Group type: EXPERIMENTAL
Intervention: Patients with DISH
Number of subjects: 25

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 25
Study: 29083139

Group type: EXPERIMENTAL
Intervention: 2D-HyFoSy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3D-HyFoSy
Number of subjects: 50
Study: 26451734

Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC; 62.5 g and 125 g) added to Fluticasone Propionate/Salmeterol (FP/SAL; 250/50 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO) added to Fluticasone Propionate/Salmeterol (FP/SAL; 250/50 g)
Number of subjects: 0
Study: 24378514

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r) monotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: LPV/r with optimized background regimens (OBRs)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: History of viral blip during virologic suppression with second-line PI-based regimen
Number of subjects: 60
Study: 22042589

Group type: EXPERIMENTAL
Intervention: Endoscopic plication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic fundoplication
Number of subjects: 60
Study: 20438516

Group type: EXPERIMENTAL
Intervention: Conventional, lactate-buffered, acidic solution (solution D)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Novel, bicarbonate/lactate-buffered neutral solution (solution P)
Number of subjects: 26
Study: 18320351

Group type: EXPERIMENTAL
Intervention: BFR + EXS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BFR + EXS (female)
Number of subjects: 100

Group type: COMPARATOR
Intervention: BFR + noEXS
Number of subjects: 100
Study: 15661548

Group type: EXPERIMENTAL
Intervention: Preoperative lymphoscintigraphy
Number of subjects: 823

Group type: COMPARATOR
Intervention: No preoperative lymphoscintigraphy
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Intraoperative gamma probe
Number of subjects: 823
Study: 12356379

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 10575158

Group type: EXPERIMENTAL
Intervention: Adapalene cream and gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tretinoin creams and gels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) 0.1% w/v
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adapalene
Number of subjects: 30

Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 30
Study: 8951962

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1.5 micrograms/kg per spray)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nicotine cigarette puffs
Number of subjects: 37
Study: 1655156

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid ligatures and muscle and skin closure
Number of subjects: 650

Group type: COMPARATOR
Intervention: Chromic catgut ligatures and muscle closure, nylon skin closure
Number of subjects: 650
Study: 6310983

Group type: EXPERIMENTAL
Intervention: Central parenteral nutrition (CPN)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN) plus enteral nutrition
Number of subjects: 19
Study: 30212395

Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Oral Contraceptive Pills (OCP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Follicular Phase
Number of subjects: 74

Group type: COMPARATOR
Intervention: Luteal Phase
Number of subjects: 74
Study: 30503595

Group type: EXPERIMENTAL
Intervention: CoreValve (CV)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Evolut R (ER)
Number of subjects: 675

Group type: COMPARATOR
Intervention: SAPIEN XT (SXT)
Number of subjects: 675

Group type: COMPARATOR
Intervention: SAPIEN 3 (S3)
Number of subjects: 675
Study: 27005937

Group type: EXPERIMENTAL
Intervention: Active tDCS stimulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 25
Study: 24559194

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP), mean dose/month 70.3 mg eq. (109.6 mg), median duration of exposure 204 days.
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 644
Study: 23255849

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 788

Group type: COMPARATOR
Intervention: Untreated SB with baseline stenosis < 50%
Number of subjects: 788

Group type: COMPARATOR
Intervention: Untreated SB
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Main branch (MB) stenosis at follow-up (%)
Number of subjects: 788
Study: 21173515

Group type: EXPERIMENTAL
Intervention: Bucolome combination therapy (BC) - bucolome 300 mg/day
Number of subjects: 195

Group type: COMPARATOR
Intervention: Warfarin monotherapy (WM)
Number of subjects: 195
Study: 17706438

Group type: EXPERIMENTAL
Intervention: FlexMaster (FM) rotary NiTi instruments
Number of subjects: 55

Group type: COMPARATOR
Intervention: EndoEze AET (EE) stainless steel oscillating instruments
Number of subjects: 55
Study: 15741469

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral social skills training (combined treatment)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 76